Fresenius Kabi Oncology Profile
Key Indicators
- Authorised Capital ₹ 50.00 Cr
as on 25-06-2024
- Paid Up Capital ₹ 48.04 Cr
as on 25-06-2024
- Company Age 21 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 240.70 Cr
as on 25-06-2024
- Revenue 7.09%
(FY 2023)
- Profit 27.35%
(FY 2023)
- Ebitda -4.37%
(FY 2023)
- Net Worth 3.98%
(FY 2023)
- Total Assets 13.65%
(FY 2023)
About Fresenius Kabi Oncology
The Corporate was formerly known as Dabur Pharma Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 50.00 Cr and a paid-up capital of Rs 48.04 Cr.
The company has closed loans amounting to ₹240.70 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Fresenius Kabi Oncology Limited India are Nikhil Kulshreshtha as COMPANY SECRETARY and Rahul Sharma as Cfo. Uday Shetty, Nikhil Kulshreshtha, Arvind Sharma, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231DL2003PLC119441
- Company No.
119441
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
18 Mar 2003
- Date of AGM
29 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Fresenius Kabi Oncology Limited offer?
Fresenius Kabi Oncology Limited offers a wide range of products and services, including TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Dacogen, Injectable Products, Oncology Drug, Pharmaceutical Medicine, Hearing Aids, BTE Hearing Aids.
Who are the key members and board of directors at Fresenius Kabi Oncology?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arvind Sharma  | Managing Director | 01-Jul-2018 | Current |
| Nikhil Kulshreshtha | Company Secretary | 21-Jul-2007 | Current |
| Rahul Sharma | CFO | 07-Mar-2022 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Uday Shetty | Director | 10-May-2019 | Current |
| Nikhil Kulshreshtha | Whole-Time Director and Company Secretary | 01-Jul-2015 | Current |
Marc Mahl  | Additional Director | 29-Aug-2023 | Current |
| Maximilian Bohmer | Additional Director | 29-Aug-2023 | Current |
Financial Performance and Corporate Structure Insights of Fresenius Kabi Oncology.
Fresenius Kabi Oncology Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.09% increase. The company also saw a substantial improvement in profitability, with a 27.35% increase in profit. The company's net worth moved up by a moderate rise of 3.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fresenius Kabi Oncology?
In 2023, Fresenius Kabi Oncology had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 29 Sep 2008 | ₹19.00 Cr | Satisfied |
Punjab National Bank Creation Date: 16 Jul 2008 | ₹15.00 Cr | Satisfied |
Hsbc Bank Plc Creation Date: 29 Sep 2006 | ₹67.00 Cr | Satisfied |
How Many Employees Work at Fresenius Kabi Oncology?
Fresenius Kabi Oncology has a workforce of 1165 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fresenius Kabi Oncology, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fresenius Kabi Oncology's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
